NAL Pharmaceuticals Ltd.-Product Pipeline Review-2015

NAL Pharmaceuticals Ltd.-Product Pipeline Review-2015

  • Products Id :- GMDHC07259CDB
  • |
  • Pages: 41
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

NAL Pharmaceuticals Ltd.-Product Pipeline Review-2015


Global Markets Direct's, 'NAL Pharmaceuticals Ltd.-Product Pipeline Review-2015', provides an overview of the NAL Pharmaceuticals Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NAL Pharmaceuticals Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of NAL Pharmaceuticals Ltd. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of NAL Pharmaceuticals Ltd.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the NAL Pharmaceuticals Ltd.'s pipeline products

Reasons To Buy

Evaluate NAL Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of NAL Pharmaceuticals Ltd. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the NAL Pharmaceuticals Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of NAL Pharmaceuticals Ltd. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of NAL Pharmaceuticals Ltd.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of NAL Pharmaceuticals Ltd. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

NAL Pharmaceuticals Ltd. Snapshot 6

NAL Pharmaceuticals Ltd. Overview 6

Key Information 6

Key Facts 6

NAL Pharmaceuticals Ltd.-Research and Development Overview 7

Key Therapeutic Areas 7

NAL Pharmaceuticals Ltd.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

NAL Pharmaceuticals Ltd.-Pipeline Products Glance 12

NAL Pharmaceuticals Ltd.-Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

NAL Pharmaceuticals Ltd.-Unknown Stage Pipeline Products 13

Unknown Products/Combination Treatment Modalities 13

NAL Pharmaceuticals Ltd.-Drug Profiles 15

pegfilgrastim 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

diclofenac sodium 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

donepezil hydrochloride 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

donepezil hydrochloride Patch 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

formoterol fumarate 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

galantamine hydrobromide 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

indomethacin 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ketoprofen 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

levocetirizine dihydrochloride 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

montelukast sodium 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

NAL-3216 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

NAL-3221 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

NAL-3223 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

nicotine 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

rizatriptan benzoate 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

sildenafil citrate 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

sufentanil citrate 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

tadalafil 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

tulobuterol 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

NAL Pharmaceuticals Ltd.-Pipeline Analysis 34

NAL Pharmaceuticals Ltd.-Pipeline Products by Target 34

NAL Pharmaceuticals Ltd.-Pipeline Products by Route of Administration 35

NAL Pharmaceuticals Ltd.-Pipeline Products by Molecule Type 36

NAL Pharmaceuticals Ltd.-Pipeline Products by Mechanism of Action 37

NAL Pharmaceuticals Ltd.-Dormant Projects 38

NAL Pharmaceuticals Ltd.-Locations And Subsidiaries 39

Head Office 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 40

Disclaimer 41

List of Tables

NAL Pharmaceuticals Ltd., Key Information 6

NAL Pharmaceuticals Ltd., Key Facts 6

NAL Pharmaceuticals Ltd.-Pipeline by Indication, 2015 8

NAL Pharmaceuticals Ltd.-Pipeline by Stage of Development, 2015 10

NAL Pharmaceuticals Ltd.-Monotherapy Products in Pipeline, 2015 11

NAL Pharmaceuticals Ltd.-Preclinical, 2015 12

NAL Pharmaceuticals Ltd.-Unknown, 2015 13

NAL Pharmaceuticals Ltd.-Pipeline by Target, 2015 34

NAL Pharmaceuticals Ltd.-Pipeline by Route of Administration, 2015 35

NAL Pharmaceuticals Ltd.-Pipeline by Molecule Type, 2015 36

NAL Pharmaceuticals Ltd.-Pipeline Products by Mechanism of Action, 2015 37

NAL Pharmaceuticals Ltd.-Dormant Developmental Projects,2015 38

List of Figures

NAL Pharmaceuticals Ltd.-Pipeline by Top 10 Indication, 2015 8

NAL Pharmaceuticals Ltd.-Pipeline by Stage of Development, 2015 10

NAL Pharmaceuticals Ltd.-Monotherapy Products in Pipeline, 2015 11

NAL Pharmaceuticals Ltd.-Pipeline by Top 10 Target, 2015 34

NAL Pharmaceuticals Ltd.-Pipeline by Top 10 Route of Administration, 2015 35

NAL Pharmaceuticals Ltd.-Pipeline by Top 10 Molecule Type, 2015 36

NAL Pharmaceuticals Ltd.-Pipeline Products by Top 10 Mechanism of Action, 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of NAL Pharmaceuticals Ltd.; NAL Pharmaceuticals Ltd. - Key Therapeutics; NAL Pharmaceuticals Ltd. - Pipeline Overview and Promising Molecules; NAL Pharmaceuticals Ltd. - News; NAL Pharmaceuticals Ltd. - Latest Updates; NAL Pharmaceuticals Ltd. - Pipeline; NAL Pharmaceuticals Ltd. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]